Background {#S0001}
==========

HIV continues to be a significant public health issue, and despite advances in prevention and care services, further work is needed to improve the well-being of people living with HIV. Globally, in 2017, more than 940,000 people died of HIV-related illnesses, 36.9 million were HIV-positive, and 1.8 million people became newly infected.[@CIT0001] By 2015, and according to the Centers for Disease Control and Prevention (CDC),[@CIT0002] Puerto Rico was among the areas with the highest estimated rates of adults and adolescents with diagnosed HIV infection (17.1 per 100,000) in the United States (US) and dependent areas. By May 2019, there were 49,675 known HIV infections in Puerto Rico.[@CIT0003] The incidence of HIV in the island is one of the highest rates in the United States[@CIT0004] and almost double the overall US Hispanic/Latino population.[@CIT0005],[@CIT0006]

In Puerto Rico, the number of HIV/AIDS cases and the number of deaths have reduced substantially throughout the years, lowering the case fatality rate from 82% in 1985 to 2% in 2016.[@CIT0007] Further, in a recent report by Marzán-Rodríguez and colleagues,[@CIT0008] it was documented that of all the deaths among people with HIV in Puerto Rico from 2006 to 2011, less than a quarter (23.5%) were related to HIV/AIDS.

People diagnosed with HIV infection may have an increased risk of developing comorbidities compared to the general population due to HIV disease itself and the use of long-term antiretroviral therapy (ART).[@CIT0009]--[@CIT0020] As HIV survival has increased and persons living with HIV enjoy life expectancies similar to those without HIV infection, they are likely to share the same comorbidities. For example, heart disease is among the comorbidities typically seen among people with HIV.[@CIT0021]--[@CIT0024] Coincidentally, heart disease was the second leading cause of death in Puerto Rico in 2013.[@CIT0025] Furthermore, the Behavioral Risk Factor Surveillance System (BRFSS) has evidenced relatively high prevalence of high cholesterol (36.7), hypertension (44.7), and diabetes (17.2%) among adult residents in Puerto Rico.[@CIT0026] In addition, nearly two-thirds are either overweight or obese, a risk factor for Coronary Heart Disease (CHD), and 43.4% has been estimated to have metabolic syndrome.[@CIT0027] In a recent assessment of CHD risk of patients attending physician offices in Puerto Rico, a substantial number of patients whose records were reviewed had risk factors for developing CHD and nearly one-third of the sample had a 10% or more 10-year risk of developing CHD.[@CIT0028]

In spite of the availability of mortality and prevalence data, there is a lack of real-world published information that would help to understand the comorbidities of people with HIV in Puerto Rico. Such information is of great importance to create awareness among health care providers and the health care system overall about the needs of taking into consideration the comorbidities of people with HIV when planning screening tests and prescribing any medication that they may need.

Methods {#S0002}
=======

To understand comorbidities in a sample of adult HIV-positive individuals in Puerto Rico, an exploratory, retrospective, cross-sectional study was conducted between January and April 2015. Data were collected from five clinics that provide services to people with HIV in different geographical areas in Puerto Rico. Clinics were purposively chosen to provide diversity to the sample and based on disposition to collaborate in the study. A State Health Department HIV Clinic, a Municipal Health Department HIV Clinic, and three private/non-governmental HIV Clinics provided the sample for the study. Both publicly funded and private-owned clinics were included.

Sample {#S0002-S2001}
------

A random sample of medical records was reviewed. At each clinic, a simple random selection was used to select medical records to be reviewed. The eligibility criteria to select and review a medical record included having an HIV diagnosis, at least 21 years of age, and being engaged in care in the selected clinic during the last 6 months. Patients with an AIDS diagnosis and pregnant women were excluded from the study due to additional medical conditions associated with their health status. Similarly, individuals enrolled in clinical trials at the time of data collection or during the last six months prior to their medical chart revision were excluded from the sample.

Measurements {#S0002-S2002}
------------

Following an extensive narrative literature review and clinician's recommendations, an in-depth data collection instrument was created, allowing for the recollection of HIV clinical information, as well as patient history of numerous comorbidities, lipids, glucose and creatinine data, and comorbidities treatment history. Patient's demographic information were also collected. All data collected were based on the information available in the medical record of each patient at the selected clinics. Comorbidities were collected from the medical record using different sources of information, including problem list, referral notes, and progress notes.

Analysis {#S0002-S2003}
--------

Data collection was completed using a paper and pen survey-like instrument, and then data were transferred to an electronic dataset using the Questionnaire Development System (QDS, Nova Research Company). Descriptive statistics (ie, mean, standard deviation) was used to summarize patient demographics, morbidity, and clinical characteristics. Multivariate analyses (ie, MANOVA, Multiple Regression Analysis) were conducted to explore differences by age and sex. For age-related analysis, 50 years of age were selected to dichotomize the sample and this is consistent with CDC definition of older people with HIV.[@CIT0029] SPSS v.20 was used to conduct all statistical procedures. Authorization was sought and received from each clinic before submitting to the Institutional Review Board (IRB). All study procedures were approved by the Human Research Subjects Protection Office of the University of Puerto Rico-Medical Sciences Campus.

Results {#S0003}
=======

Demographic and clinical characteristics {#S0003-S2001}
----------------------------------------

As included in [Table 1](#T0001){ref-type="table"}, a total of 250 medical records were reviewed. Of these, 179 were of men (71.6%) and 71 (28.4%) of women. The mean age of the subjects was 47.9 years and, on average, they had been living with HIV for 9.3 years. Data availability for this research did not differ by sex. Certainly, as a result of good practices in HIV care, patients who have been living longer with a diagnosis of HIV infection had more information in their medical records.Table 1General characteristics of a sample of adults with HIV in Puerto RicoCharacteristicsTotal (N=250)Men (N=179)Women (N=71)μSDμSDΜSDAge47.912.646.313.351.89.8Weight (lbs)169.938.7170.734.0168.148.7Height (in)67.46.069.06.263.32.7Body mass index26.66.025.55.029.37.4Age when diagnosed with HIV38.011.637.012.040.69.8Age of HIV treatment initiation^a^39.612.537.713.144.79.3Diagnosis to HIV treatment (months)^a^9.417.19.015.510.620.8Years living with HIV9.38.18.88.010.68.0Years in HIV treatment^a^3.43.63.03.64.23.4Days since last CD4 test80.275.779.865.281.197.6CD4 count (cells/mm^3^)723.8363.2698.7326.8786.6437.6CD4 percentage34.830.434.635.134.930.4Days since last viral load test81.484.682.776.778.1102.2Viral load count^b^ (copies/mL)3431.114,342.94174.316,670.51628.75348.1[^1]

On average, the age for HIV diagnosis among participants was 38 years; they spent 9.4 years from HIV diagnosis to treatment initiation and have been on treatment for 3.4 years. The mean CD4 count was 723.8 cells/mm^3^, and for viral load, the count was 3,431.1 copies/mL.

Considering the role that body max index (BMI) may have with certain comorbidities, bivariate analyses were conducted to assess the BMI by sex and age. As included in [Table 2](#T0002){ref-type="table"}, more than a third of the study sample was overweight. Among men, 62.6% had an abnormal BMI, while 35.2% of the women were obese. These differences were statistically significant by sex.Table 2Bivariate analysis of body mass index categorized by sex and age in a sample of adults with HIV in Puerto RicoComorbidityTotal (N=250)Men (N=179)Women (N=71)*p*-Value\<50 yrs (N=135)50+ yrs (N=114)*p*-ValueN%n%n%n%n%Body mass index**0.001**0.360\<202610.42111.757.0128.91412.320--\<258433.66737.41723.95037.03328.925--\<309036.06636.92433.84432.64640.430+5020.02514.02535.22921.52118.4[^2]

When BMI was assessed by age groups (younger than 50 years of age and 50 years of age and older), more than a third (37.0%) of those younger than 50 years of age had a normal BMI, and 40.4% of those 50 years of age or older were overweight. These differences by age groups were not found to be statistically significant. See [Table 2](#T0002){ref-type="table"} for details.

Comorbidities {#S0003-S2002}
-------------

The vast majority (97.6%) of the participants had been diagnosed with at least one HIV comorbidity during the 6-month period that preceded data collection. Among the most common comorbidities for both men and women were dyslipidemia (total: 60.8%; men: 60.8%; women: 69.0%), alcohol abuse (total: 48.8%; men: 58.1%; women: 25.4%), and hypertension (total; 39.6%; men: 36.9%; women: 46.5%). [Table 3](#T0003){ref-type="table"} includes all the comorbidities found in the study sample. In general, the mean amount of comorbidities reported in the sample was 3.7 (SD=1.9). Men reported significantly less comorbidities (Mean=3.5, SD=1.9) than women (Mean=4.1, SD=1.9; *p*=0.035).Table 3Comorbidities in a sample of adults with HIV in Puerto RicoComorbidityTotalMen (N=179)Women (N=71)*p*-Valuen%n%N%Prevalence of comorbidities24497.617497.27098.60.519Dyslipidemia15260.810357.54969.00.094Alcohol miuse12248.810458.11825.4**\<0.001**Hypertension9939.66636.93346.50.161Cigarette Smoking8935.66737.42231.00.337Overweight6726.84625.72129.60.532Diabetes mellitus4919.63217.91723.90.276Depression4819.22916.21926.80.056Obesity4819.22514.02332.4**0.001**Substance misuse4216.83318.4912.70.272Human papilloma virus (HPV)4216.82212.32028.2**0.002**Chronic hepatitis C3313.22413.4912.70.878Vitamin D deficiency249.6158.4912.70.298Hypothyroidism208.095.01115.5**0.006**Chronic hepatitis B124.873.957.00.330Chronic kidney disease104.052.857.00.153Lipodystrophy93.684.511.40.452Osteoporosis93.621.179.9**0.003**Benign prostatic hyperplasia72.873.9------Peripheral vascular disease62.452.811.40.999Revascularization Procedure62.442.222.80.999Acute coronary syndrome (ACS)52.052.80--0.326Pre-diabetes52.031.722.80.624Angina pectoris41.631.711.40.999Previous stroke/TIA20.80--22.80.080Congestive heart failure10.410.60--0.999[^3]

As included in [Table 3](#T0003){ref-type="table"}, when all comorbidities where assessed by sex, men were more likely to have been diagnosed with alcohol misuse (*p*\<0.001) while women were more likely to have been diagnosed with obesity (*p*=0.001), HPV infection (*p*=0.002), hypothyroidism (*p*=0.006), and osteoporosis (*p*=0.003).

The data collection instrument also included a general clinical assessment of indicators of common comorbidities and chronic conditions. As included in [Table 4](#T0004){ref-type="table"}, data on blood pressure, lipid panel, and blood chemistry tests were obtained from medical records. Overall, the research sample showed slightly higher levels for triglycerides, glucose, hemoglobin A1c, and systolic blood pressure when compared to normal values. When analyzed by sex, women had LDL levels slightly higher than normal. There were no statistically significant findings when these clinical indicators were assessed by age.Table 4Blood pressure, lipid panel, and blood chemistry tests data from a sample of adults with HIV in Puerto RicoClinical indicatorTotal (N=250)Men (N=179)Women (N=71)μSDΜSDμSDNon-HDL^a^36.731.037.532.035.029.3Total cholesterol177.941.7175.042.5185.338.8HDL46.116.144.614.850.018.4LDL99.834.198.334.2103.733.7Triglycerides185.7179.1191.3194.9171.7131.7Glucose (FPG)101.633.1101.431.3101.9131.7Hemoglobin A1c (HgbA1c)^b^6.11.56.21.76.10.9Blood pressure Systolic128.317.5127.616.4130.119.8 Diastolic79.410.779.011.080.410.0Creatinine (Cr)1.00.61.00.60.80.7[^4]

As included in [Table 5](#T0005){ref-type="table"}, the most common comorbidity treatments were multivitamins (71.5%), lipid-lowering therapy (57.6%), and antihypertensive agents (37.6%). These were also the most common treatments when stratified by sex. The mean amount of medications in the study sample was of 2.1 (SD =16). Men were using less medications (Mean =2.5, SD =1.5) than women (Mean =3.5, SD =1.6, *p*\<0.001).Table 5Treatment history of a sample of adults with HIV in Puerto RicoTreatmentTotal (N=250)Men (N=179)Women (N=71)*p*-Valuen%n%n%Anti-acids83.231.757.0**0.030**Antihyperglycemic agents4116.43016.81115.50.807Antihypertensive agents9437.66335.23143.70.213Asthma medications2811.2179.51115.50.175Cholecalciferol8032.05128.52940.80.059Dehydroepiandrosterone31.231.70----H2 blockers4216.82514.01723.90.057Levothyroxine156.073.9811.3--Lipid-lowering therapy14457.69754.24766.20.083Multivitamins17871.512368.75578.60.121Opioid pain medication20.821.10----Proton pump inhibitors4618.42111.72535.2**\<0.001**[^5]

Further, when compared to men, women were more likely to be using proton pump inhibitors (*p*\<0.001) and anti-acids (*p*=0.030, See [Table 5](#T0005){ref-type="table"}).

To explore age-related factors associated with comorbidities, the sample was dichotomized in two age groups, younger than 50 years of age and 50 years of age and older. As included in [Table 6](#T0006){ref-type="table"}, the group younger than 50 years were more likely to have an alcohol abuse diagnosis (*p*=0.006) while the older individuals (50 years of age or older) were more likely to have been diagnosed with dyslipidemia (*p*\<0.001), hypertension (*p*\<0.001), and diabetes mellitus (*p*\<0.001).Table 6Bivariate analysis of the prevalence of comorbidities by age in a sample of adults with HIV in Puerto RicoComorbidity\<50 yrs (N=135)50+ yrs (N=114)*p*-Valuen%N%Prevalence of comorbidities13197.011399.10.242Alcohol abuse7757.04539.5**0.006**Dyslipidemia6648.98675.4**\<0.001**Cigarette smoking5540.73429.80.073Hypertension3828.16153.5**\<0.001**Overweight3425.23328.90.505HPV2820.71412.30.076Substance misuse2720.01513.20.151Obesity2720.02118.40.753Depression2720.02118.40.753Diabetes mellitus1511.13429.8**\<0.001**Chronic hepatitis C139.62017.50.067Vitamin D deficiency107.41412.30.194Hypothyroidism96.7119.60.388Chronic hepatitis B75.254.40.769Angina pectoris32.210.90.627Chronic kidney disease32.276.10.193Revascularization procedure21.543.50.417Pre-diabetes21.532.60.663Lipodystrophy21.576.10.084Osteoporosis21.576.10.084Benign prostatic hyperplasia^a^21.957.10.114Previous stroke/TIA10.710.90.999Peripheral vascular disease10.754.40.096Acute coronary syndrome (ACS)0--54.4**0.019**Congestive heart failure0--10.90.458Tuberculosis0--0----Fat accumulation0--0----[^6]

Considering the role of age in developing comorbidities, a multivariate analysis adjusting by sex and age was conducted. Findings suggest that women were more likely than men to have been diagnosed with obesity (aOR=3.197; 95% CI: 1.625--6.290) and depression (aOR=1.986; 95% CI: 1.008--3.914). Also, as included in [Table 7](#T0007){ref-type="table"}, they were slightly more likely than men to have been diagnosed with alcohol abuse (aOR=0.266; 95% CI: 0.143--0.496), HPV infection (aOR=0.282; 95% CI: 0.136--0.584), and hypothyroidism (aOR=0.300; 95% CI: 0.116--0.779). Comorbidities associated with been older than 50 years of age were dyslipidemia (aOR=3.075; 95% CI: 1.769--5.346), hypertension (aOR=2.852; 95% CI: 1.670--4.871), HPV infection (aOR=2.547; 95% CI: 1.205--5.385), and diabetes mellitus (aOR=3.331; 95% CI: 1.684--6.589).Table 7Multivariate analysis of the prevalence of comorbidities by age and sex in a sample of adults with HIV in Puerto Rico^a^ComorbiditySexAgeMenWomen\<50 yrs50+ yrsRef.aOR (95% CI)Ref.aOR (95% CI)Prevalence of comorbidities11.258 (0.133--11.891)13.313 (0.354--31.040)Alcohol abuse1**0.266 (0.143--0.496)**10.595 (0.349--1.013)Dyslipidemia11.288 (0.697--2.379)1**3.075 (1.769--5.346)**Cigarette smoking10.821 (0.450--1.498)10.641 (0.374--1.098)Hypertension11.181 (0.658--2.119)1**2.852 (1.670--4.871)**Overweight11.162 (0.623--2.168)11.177 (0.663--2.088)HPV1**0.282 (0.136--0.584)**1**2.547 (1.205--5.385)**Drug abuse10.703 (0.312--1.581)10.644 (0.320--1.298)Obesity1**3.197 (1.625--6.290)**10.700 (0.357--1.372)Depression1**1.986 (1.008--3.914)**10.785 (0.407--1.514)Diabetes mellitus11.118 (0.558--2.240)1**3.331 (1.684--6.589)**Chronic hepatitis C10.790 (0.340--1.836)12.085 (0.971--4.474)Vitamin D deficiency10.706 (0.288--1.733)10.611 (0.255--1.462)Hypothyroidism1**0.300 (0.116--0.779)**10.859 (0.331--2.230)Chronic hepatitis B11.990 (0.591--6.707)10.727 (0.217--2.439)Angina pectoris11.020 (0.100--10.432)10.388 (0.038--3.941)Chronic kidney disease12.175 (0.592--7.992)12.461 (0.603--10.047)Revascularization procedure11.046 (0.181--6.054)12.398 (0.418--13.768)Pre-diabetes11.513 (0.237--9.656)11.655 (0.261--10.516)Lipodystrophy10.217 (0.026--1.808)1**5.348 (1.073--26.656)**Osteoporosis1**7.831 (1.548--39.622)**12.929 (0.573--14.986)Peripheral vascular disease10.345 (0.039--3.075)17.202 (0.816--63.535)[^7]

Discussion {#S0004}
==========

While not a representative sample of people with HIV in Puerto Rico, data from participants in this study are similar to the general epidemiological data available of people with HIV and to other studies conducted among people with HIV in Puerto Rico. The ratio of women and men with HIV in the sample (1:3) is consistent with surveillance data from the Puerto Rico Department of Health.[@CIT0007] Other general similarities with previously published research are participant's average age[@CIT0030],[@CIT0031] and hemoglobin levels.[@CIT0032]

Consistent with other studies among people with HIV, the sample studied in this research evidenced comorbidities associated with cardiovascular diseases.[@CIT0033] For example, dyslipidemia is a comorbidity reported among other similar populations. In our study, the prevalence of dyslipidemia was higher than the rates reported among HIV-positive adults (43.7% Latinos) in the Bronx, NY (60.8% vs 48%).[@CIT0033]

The five most common comorbidities in this sample of people with HIV in Puerto Rico slightly varied from the findings from a study published by Miranda and colleagues[@CIT0034] also encompassing a sample of HIV-positive individuals in the island. In their longitudinal study among people with HIV, they found that the most common comorbidities were cardiovascular diseases, renal and hepatic disorders, osteopenia, endocrine and metabolic abnormalities, and non-AIDS defining neoplasm. The difference between these studies might be the inclusion/exclusion of patients with an AIDS diagnosis and the longitudinal nature of the study conducted by Miranda and colleagues.[@CIT0034] It is our understanding that our findings illustrate a better picture of the comorbidities of people with HIV in Puerto Rico who are engaged in care.

Another study conducted among people with HIV in Puerto Rico found morbidity and mortality associated with kidney disease.[@CIT0030] However, in this sample, history of comorbidity with kidney disease was low (\<20%) and no alarming levels of clinical indicators of kidney disease (ie, creatinine) were reported.

Consistent with other research findings from studies with people with HIV, when compared to men, women show higher rates of overweight and obesity.[@CIT0031],[@CIT0035] A study conducted by Ramirez-Marrero and colleagues[@CIT0036] reported the risk for metabolic syndrome among people with HIV in Puerto Rico. Consistent with their findings, our analysis supports the needs for monitoring cardiovascular indicators among people with HIV. Furthermore, our findings -- consistent with those of Maldonado-Martínez and colleagues[@CIT0035] from a sample of people with HIV in Puerto Rico -- support the needs for comprehensive approaches to reduce the risk for metabolic syndrome and HIV disease progression, including monitoring BMI as well as chronic and behavioral precursors.

The most common comorbidities found in older groups after controlling by sex are consistent with findings reported in the scientific literature. A significant finding in this regard is the fact that dyslipidemia among those participants 50 years and older was 3.075 (95% CI: 1.769--5.346) more common than among those younger than 50 years. This is more than double the likelihood of this correlation (OR=1.42) found in a sample of individuals 45 years or older from The Bronx, New York[@CIT0033] Future studies among patients older than 50 years are recommended to assess HIV-induced accelerated aging.

While the purpose of this study was not to assess HIV comorbidities with mental illnesses in details, significant rates of depression and substance abuse were found. Due to the fact that injecting drug use is one of the main risk factors for HIV infection in Puerto Rico, it is not surprising to identify these comorbidities in a sample of people with HIV in the archipelago. In our study, 48.8% of the sample reported alcohol misuse. In other studies of people with HIV, alcohol use had varied from 5% (measuring alcohol abuse) to 51.5%.[@CIT0032],[@CIT0033],[@CIT0037] Nonetheless, different from other investigations conducted in Puerto Rico,[@CIT0034],[@CIT0035] in our study we found that, after adjusting by age and sex, women had higher likelihood of been diagnosed with alcohol misuse. This finding, as other findings reported in this manuscript, requires further analysis considering the role that sex differences may play in access and healthcare use.[@CIT0038]

On the other hand, cigarette smoking was reported among more than a third of the participants (35.6%) and substance misuse was documented in 16.8% of the study sample. Other studies have reported rates from 13% to 59.4% of cigarette smoking[@CIT0033],[@CIT0036],[@CIT0039] and from 3% (reporting only drug abuse) to 43.7% of substance misuse.[@CIT0032],[@CIT0033] The findings of our study are consistent with those from other studies reporting higher rates of substance misuse (non-alcohol or cigarettes) among men.[@CIT0034],[@CIT0035]

Findings from this study should be considered in context with population-based data available regarding the most common comorbidities in Puerto Rico. For example, it has been documented that among adults in Puerto Rico (irrespective of their HIV status) about 36.7% (36.6% among men; 36.7% among women) have reported a high level of cholesterol in blood;13.1% (20.5% among men; 6.8% among women) have reported binge drinking; 11.3% have reported current smoker status (16.9% among men; 6.4% among women); and 68.3% of the population is overweight or obese (70.2% among men; 66.6% among women).[@CIT0026] These population trends have an impact in the assessment of comorbidities among people with HIV in Puerto Rico and the interpretation and comparisons with findings from studies conducted with populations elsewhere. Moreover, these population health indicators highlight the significance of the findings of this study and the need to integrate public health prevention efforts.

Research findings should be considered within the limitations of this study. This research project was limited to the revision of 250 medical charts from 5 clinics. These clinics were selected following a purposive sampling approach and the 250 medical charts reviewed were chosen based on a simple random selection. Further, due to the retrospective and cross-sectional nature of this study, data are limited to the information available from the chart reviews. No data were collected related to the use of ART limiting the analysis of the relationship of HIV-related medication and comorbidities. Similarly, the charts selected for revision are of those participants who met inclusion criteria and were active in medical care. As a result of all the aforementioned limitations, findings are not generalized to people with HIV in Puerto Rico or elsewhere.

Conclusion {#S0005}
==========

Based on a comprehensive narrative analysis of the scientific literature, and to the best of our knowledge, this is the first observational study that assessed comorbidities among people with HIV in Puerto Rico and one of the few among Latino/Hispanic populations. Despite the limitations of the study and consistent with other studies, cardiovascular diseases -- specifically dyslipidemia and hypertension -- were found to be common among people with HIV in Puerto Rico. Certain characteristics such as age, sex, and use of medication may play a role in the comorbidities among people with HIV in Puerto Rico. Findings support the need for creating awareness of the comorbidities of people living with HIV, particularly when implementing prevention strategies and prescribing drug therapy. Further, this information should be available to physicians and other health care providers to improve differentiated and comprehensive approaches to address the needs of people with HIV.
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[^1]: **Notes:** ^a^N=103 (Men=74, Women=29). ^b^n=137 (Men=97, Women=40).

[^2]: **Note:** Values in bold represent statistical significance (\<0.05).

[^3]: **Note:** Values in bold represent statistical significance (\<0.05).

[^4]: **Notes:** ^a^N=167 (Male=113; Female=54). ^b^n=93 (Male=65; Female=28).

[^5]: **Note:** Values in bold represent statistical significance (\<0.05).

[^6]: **Notes:** ^a^Only men were included when analyzing benign prostatic hyperplasia (n=178). Values in bold represent statistical significance (\<0.05).

[^7]: **Notes:** ^a^Acute coronary syndrome, congestive heart failure, tuberculosis, previous stroke/TIA, and fat accumulation were excluded from this analysis due to lack of reported cases in certain subgroups. Benign prostatic hyperplasia was also excluded from the analysis. Values in bold represent statistical significance (\<0.05).
